JLP 2004
Alternative Names: JLP-2004Latest Information Update: 22 Jan 2024
At a glance
- Originator Jeil Pharmaceutical
- Class
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Unspecified
Most Recent Events
- 05 Oct 2023 Phase-I clinical trials in Unspecified in South Korea (unspecified route) (NCT06169059)